JP5453254B2 - 眼圧降下用の治療用置換シクロペンタン類 - Google Patents

眼圧降下用の治療用置換シクロペンタン類 Download PDF

Info

Publication number
JP5453254B2
JP5453254B2 JP2010515212A JP2010515212A JP5453254B2 JP 5453254 B2 JP5453254 B2 JP 5453254B2 JP 2010515212 A JP2010515212 A JP 2010515212A JP 2010515212 A JP2010515212 A JP 2010515212A JP 5453254 B2 JP5453254 B2 JP 5453254B2
Authority
JP
Japan
Prior art keywords
chloro
mmol
carboxylic acid
thiophene
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010515212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532379A5 (enExample
JP2010532379A (ja
Inventor
ディヴィッド ダブリュー オールド
ヴィン エックス ヌゴ
マーク ホロボスキー
マリー エフ ポズナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2010532379A publication Critical patent/JP2010532379A/ja
Publication of JP2010532379A5 publication Critical patent/JP2010532379A5/ja
Application granted granted Critical
Publication of JP5453254B2 publication Critical patent/JP5453254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47G—HOUSEHOLD OR TABLE EQUIPMENT
    • A47G19/00—Table service
    • A47G19/02—Plates, dishes or the like
    • A47G19/06—Plates with integral holders for spoons, glasses, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2010515212A 2007-07-03 2008-06-30 眼圧降下用の治療用置換シクロペンタン類 Expired - Fee Related JP5453254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94790407P 2007-07-03 2007-07-03
US60/947,904 2007-07-03
PCT/US2008/068716 WO2009006370A1 (en) 2007-07-03 2008-06-30 Therapeutic substituted cyclopentanes for reducing intraocular pressure

Publications (3)

Publication Number Publication Date
JP2010532379A JP2010532379A (ja) 2010-10-07
JP2010532379A5 JP2010532379A5 (enExample) 2011-08-18
JP5453254B2 true JP5453254B2 (ja) 2014-03-26

Family

ID=39941423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515212A Expired - Fee Related JP5453254B2 (ja) 2007-07-03 2008-06-30 眼圧降下用の治療用置換シクロペンタン類

Country Status (12)

Country Link
US (2) US9591935B2 (enExample)
EP (1) EP2170345B1 (enExample)
JP (1) JP5453254B2 (enExample)
KR (1) KR20100051803A (enExample)
CN (1) CN101795692B (enExample)
AU (2) AU2008269965A1 (enExample)
CA (1) CA2692572A1 (enExample)
DK (1) DK2170345T3 (enExample)
ES (1) ES2401920T3 (enExample)
NZ (1) NZ582705A (enExample)
RU (2) RU2010103149A (enExample)
WO (1) WO2009006370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4289416A3 (en) 2009-05-18 2024-01-03 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US8299068B2 (en) * 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
JP6569661B2 (ja) * 2014-02-27 2019-09-04 小野薬品工業株式会社 選択的ｅｐ２アゴニスト活性を有する化合物
ES2837399T3 (es) * 2015-07-23 2021-06-30 Ono Pharmaceutical Co Derivados de ácido 2-(octahidrociclopenta(b)piran-2-il)1,3-tiazol-4-carboxílico y compuestos relacionados como agonistas de EP2 con actividad reductora de la presión intraocular
WO2019108729A1 (en) * 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307882A (en) * 1939-12-04 1943-01-12 Freud Joseph Combined food and beverage server
US3980700A (en) * 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
US4149007A (en) * 1977-06-23 1979-04-10 Miles Laboratories, Inc. C14 Phenyl-substituted derivatives of prostaglandin analogues
US5390798A (en) * 1991-11-07 1995-02-21 G'-Ka International, Inc. Food and beverage support tray with beverage vessel cutout
US5323910A (en) * 1992-08-07 1994-06-28 Van De Graaf Jr Pieter A Party plate
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
US5593062A (en) * 1995-10-10 1997-01-14 Martin; Melvin E. Social serving plate
US5727678A (en) * 1996-06-12 1998-03-17 Chen; Chin Chen Two-in-one paper dish and cup holder
US5950856A (en) * 1997-04-15 1999-09-14 Cinque; Richard Plate and cup holder
US6264026B1 (en) * 1997-04-15 2001-07-24 Vincent H. Bradley Food, beverage and utility tray
US6531485B2 (en) * 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
EP1108426A3 (en) 1999-12-02 2002-10-02 Pfizer Products Inc. Use of prostaglandin agonists to treat erectile dysfunction or impotence
KR20040023707A (ko) * 2001-07-31 2004-03-18 수캄포 아게 안내압항진 및 녹내장의 치료
US6651836B1 (en) * 2002-07-03 2003-11-25 Leonard L. Hofheins Hand-held plate for holding a beverage container and food
NZ555945A (en) 2005-01-14 2011-01-28 Allergan Inc Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
JP5532302B2 (ja) 2006-07-10 2014-06-25 アラーガン インコーポレイテッド 治療化合物
US20080015219A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
BRPI0714885B8 (pt) * 2006-07-11 2021-05-25 Allergan Inc compostos terapêuticos e seu uso

Also Published As

Publication number Publication date
AU2008269965A1 (en) 2009-01-08
CN101795692A (zh) 2010-08-04
CN101795692B (zh) 2013-06-12
EP2170345A1 (en) 2010-04-07
WO2009006370A1 (en) 2009-01-08
NZ582705A (en) 2012-06-29
AU2014203599A1 (en) 2014-07-17
CA2692572A1 (en) 2009-01-08
US20170144999A1 (en) 2017-05-25
US20110062165A1 (en) 2011-03-17
EP2170345B1 (en) 2013-03-06
KR20100051803A (ko) 2010-05-18
JP2010532379A (ja) 2010-10-07
US9765065B2 (en) 2017-09-19
US9591935B2 (en) 2017-03-14
ES2401920T3 (es) 2013-04-25
RU2010103149A (ru) 2011-08-10
DK2170345T3 (da) 2013-05-13
RU2014105895A (ru) 2015-08-27

Similar Documents

Publication Publication Date Title
JP5453254B2 (ja) 眼圧降下用の治療用置換シクロペンタン類
TWI249520B (en) 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
JP5410438B2 (ja) 治療用置換ラクタム類
JP5432724B2 (ja) 治療薬としての置換アリールシクロペンテン類
JP2009543792A (ja) 抗緑内障薬としてのシクロペンタン誘導体
CN101952261B (zh) 具有前列腺素活性的取代环戊烷
JP2004537529A (ja) 医薬としてのシクロペンタンヘプタン（ヘプテン）アシルスルホンアミド，２−アルキルもしくは２−アリールアルキル、または２−ヘテロアリールアルケニル誘導体
JP5453111B2 (ja) 治療薬としての置換アリールシクロペンタン類
JP5566902B2 (ja) プロスタグランジン活性を有する置換シクロペンタン類
JP5566696B2 (ja) 緑内障または上昇眼内圧の治療用ガンマ‐ラクタム類
RU2481342C9 (ru) Терапевтические замещенные лактамы
HK1181392A (en) Substituted cyclopentanes having prostaglanding activity
AU2006283208A1 (en) Sulfonamides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140106

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees